Skip to content

Dual therapy with Kaletra and 3TC works well regardless of viral load

Pedro Cahn, Fundacion Huesped, Argentina, presents results of the Gardel study at EACS2013. Photo by Liz Highleyman, hivandhepatitis.com

Are antiretroviral switch or simplification studies of benefit for patients?

Boosted darunavir monotherapy works well in two studies

High failure rate for people with low CD4 nadirs in Kaletra monotherapy study

EACS: Kaletra monotherapy may need excellent adherence to work

Two-drug maintenance with tenofovir-efavirenz less effective than triple therapy

BHIVA: Kaletra monotherapy has benefits in clinical practice for highly treatment-experienced

OK study continues to show potency of Kaletra monotherapy after 72 weeks

Could monotherapy with Kaletra become an option for HIV treatment?